GlassScriptPhysician profile
Rugen Alda
NPI 1750340022
$12,840.74
in general payments reported to CMS, 2019-2025
53 companies · $1,374 in 2025
The $1,374 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,069 · 2020: $1,729 · 2021: $2,507 · 2022: $2,166 · 2023: $1,245 · 2024: $1,751 · 2025: $1,374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,349 · Long Term Medical Supply Or Device Loan: $19.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,349.45 |
| Long Term Medical Supply Or Device Loan | $19.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,759.62 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,470.61 | 2021-2025 | Vraylar, Ubrelvy, Linzess |
| Astrazeneca Pharmaceuticals LP | $1,015.11 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Sanofi-Aventis U.S. LLC | $592.39 | 2019-2023 | |
| Biohaven Pharmaceuticals, INC. | $581.23 | 2021 | |
| Pfizer INC. | $571.25 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $568.20 | 2021-2025 | |
| Amgen INC. | $549.63 | 2019-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $530.05 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $515.95 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $453.64 | 2019-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $447.80 | 2021-2025 | Rexulti, Nuedexta |
| Takeda Pharmaceuticals U.S.A., INC. | $342.09 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $332.47 | 2022 | |
| Novartis Pharmaceuticals Corporation | $324.68 | 2019-2024 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rugen Alda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.